

NCHIV 2020 – background information for accreditation

Netherlands Conference on HIV Pathogenesis, Epidemiology, Prevention & Treatment

24 November 2020, KIT, Amsterdam

**Oral abstracts will be selected by an extensive review committee consisting of experts from the fields of HIV pathogenesis, epidemiology, prevention and treatment. The committee will select the abstracts for oral presentation based on scientific merit and relevance to the field; contributions from young researchers are particularly encouraged.*

Session 1: Title to be confirmed

Chairs: To be confirmed.

Novel Antiretroviral Treatments and Strategies

Prof. Daniel Kuritzkes (Brigham & Women's Hospital, Boston, MA, USA)

3 selected oral abstracts, where possible relating to the subject of the plenary or more generally to treatment and/or prevention of HIV/AIDS*

Daniel Kuritzkes is the Harriet Ryan Albee Professor of Medicine at Harvard Medical School and Chief of the Division of Infectious Diseases at Brigham and Women's Hospital in Boston, Massachusetts. He received his B.S. and M.S. degrees from Yale University and his M.D. from Harvard Medical School. Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He served as a member of the NIH Office of AIDS Research Advisory Council and as a member of the U.S. Department of Health and Human Services panel on guidelines for antiretroviral therapy. He has been a member of several editorial boards and serves as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, and HIV eradication.

At NCHIV 2020, Prof. Kuritzkes will speak on the topic of 'Novel Antiretroviral Treatments and Strategies', providing an overview of the latest data on novel ARV's in advanced stages of clinical development and how these may impact and be best positioned as part of future treatment strategies.

Depending on abstracts submitted to the conference, this will be followed by a selection of oral abstract presentations linked to the plenary and/or aspects of HIV treatment and/or prevention more generally.

Session 2: Title to be confirmed

Chairs: To be confirmed.

The HIV epidemic in the Netherlands: an update

Anders Boyd, Ard van Sighem, Colette Smit & Ferdinand Wit (Stichting HIV Monitoring; AIGHD; AMC-UvA; GGD Amsterdam)

HIV and Tuberculosis

Dr. Sabine Hermans (AIGHD; AMC-UvA, Amsterdam, the Netherlands)

3 selected oral abstracts where possible linked to the subject of the plenary or relating to the subject of epidemiology of HIV/AIDS more generally*

Senior researchers from Stichting HIV Monitoring, under the direction of Prof. Peter Reiss (SHM Director) will provide the conference participants with an update on the HIV epidemic in the Netherlands, based on the latest Monitoring Report published by Stichting HIV Monitoring.

Sabine Hermans, MD MSc PhD, is a scientific staff member at AIGHD and Assistant Professor in the Department of Global Health, and Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam.. Dr. Hermans' has extensive research experience concerning the epidemiology of HIV and TB (co-)infection, in particular recurrent TB, as well on how to optimize health care delivery strategies in sub-Saharan Africa. In this field she has undertaken historical and cost-effectiveness research, and led a prospective study of an mHealth intervention to improve TB treatment completion in Uganda.

Dr. Hermans will give a talk at NCHIV 2020 on the topic of 'HIV and Tuberculosis', she will highlight innovations and other issues related to the topic, which are relevant to the Dutch setting as well as globally.

Depending on abstracts submitted to the conference, this will be followed by a selection of oral abstract presentations on various aspects of the prevention and/or treatment of HIV-associated co-infections, including tuberculosis.

Session 3: Title to be confirmed

Chairs: To be confirmed.

The Critical Role of Socio-Behavioral Sciences in the Multi-Disciplinary HIV Cure Research Era

Dr. Karine Dubé (University of North Carolina, Gillings School of Public Health, USA)

3 selected oral abstracts where possible relating to the subject of the plenary or to the subject of social science research in HIV treatment and/or prevention more generally*

Dr. Karine Dubé is a socio-behavioral researcher and an experienced research program manager. Her current work focuses on integrating socio-behavioral research as part of actual HIV cure trials in the United States. Dr. Dubé bridges biomedical, socio-behavioral sciences and ethics in infectious diseases research. She has close to 15 years of experience in infectious diseases-related work, including Ebola and HIV prevention and cure research. She has also worked in the areas of malaria control and treatment, HSV-2 prevention and treatment, sexual and reproductive health and family planning.

At NCHIV 2020, Dr. Dubé will give a talk entitled The Critical Role of Socio-Behavioral Sciences in the Multi-Disciplinary HIV Cure Research Era.

This will be followed by a selection of oral abstract presentations where possible linked to the subject of the plenary or social science research in HIV treatment and/or prevention more generally.

Session 4: Title to be confirmed

Chairs: To be confirmed

HIV and Hepatitis B cure

Prof. Sharon Lewin (University of Melbourne, Australia)

3 selected oral abstracts where possible relating to the subject of the plenary or HIV (and HBV) pathogenesis more generally*

Leading infectious diseases expert, Professor Sharon Lewin, is the inaugural Director of the Doherty Institute in Melbourne, Australia. She is also a Professor of Medicine at The University of Melbourne and a National Health and Medical Research Council (NHMRC) Practitioner Fellow. As an infectious diseases physician as well as a basic scientist, her laboratory focuses on basic, translational and clinical research aimed at finding a cure for HIV and hepatitis B. She is also the Chief Investigator of a NHMRC Centre of Research Excellence (CRE), The Australian Partnership for Preparedness Research on Infectious Diseases Emergencies (APPRISE) that aims to bring together Australia's leading experts in clinical, laboratory and public health research to address the key components required for a rapid and effective emergency response to infectious diseases.

Prof. Lewin in her talk at NCHIV 2020 will focus the topic of 'HIV cure', where possible incorporating similarities and differences between the HIV and HBV cure research agendas.

The oral abstracts during this session where possible linked to the subject of the plenary and/or HIV (and HBV) pathogenesis more generally.